Top

Published in:

01-05-2006 | Original Article

Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

Authors: Alessandra Fabi, Gianluigi Ferretti, Paola Papaldo, Nello Salesi, Mariangela Ciccarese, Vito Lorusso, Paolo Carlini, Armando Carpino, Marcella Mottolese, Anna Maria Cianciulli, Diana Giannarelli, Isabella Sperduti, Alessandra Felici, Francesco Cognetti

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2006

Abstract

Background: The aim of the study was to assess the toxicity profile, activity in terms of response rate, time to progression, overall survival, and quality of life of pegylated liposomal doxorubicin (PLD) and gemcitabine combination in chemo-naïve and pretreated metastatic breast cancer (MBC) women. Methods: Patients were eligible if they had disease progression to prior chemotherapy (anthracycline-including or not) for early breast cancer or MBC. Patients received PLD 25 mg/m² intravenously on day 1 plus gemcitabine 800 mg/m² intravenously on days 1 and 8 of each 21-day cycle. Results: Of 50 patients enrolled, 37 had received prior adjuvant chemotherapy (24 with an anthracycline) and 23 prior chemotherapy for metastatic disease (6 with an anthracycline). Two complete responses and 20 partial responses were achieved in 46 assessable patients (overall response rate: 47.8%). Responses were observed in 14 (46.6%) of 30 patients with previous anthracycline exposure. Median response duration was 7 months, median duration of clinical benefit 8 months, time to progression 7 months. At a median follow-up of 10 months, 79.4% patients were alive at 1 year. No neutropenic complication was observed. Non-hematological toxicities were mild. One patient previously treated with an anthracycline developed a transient decrease (26%) in the left ventricular ejection fraction, with cardiac function recovering within 6 months. Conclusion: Because of the non-overlapping toxicity profiles of both PLD and gemcitabine, this combination can be regarded as a reliable therapeutic option for patients who have failed previous treatments, including anthracycline, for MBC.

Perez AT, Domenech GH, Frankel C, Vogel CL (2002) Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest 20(Suppl 2):22–29CrossRefPubMed

Gabizon A, Martin F (1994) Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 54(Suppl 4):15–21

Gabizon AA (1994) Liposomal anthracyclines. Hematol Oncol Clin North Am 8:431–450PubMed

Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 54(Suppl 4):15–21PubMedCrossRef

O’Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX^TM/Doxil^®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–449PubMedCrossRef

Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22(19):3893–3901CrossRefPubMed

Possinger K, Kaufman M, Coleman R et al (1999) Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anti-Cancer Drugs 10:155–162PubMedCrossRef

Carmichael J, Possinger K, Philip P et al (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13:2731–2736PubMed

Blackstein M, Vogel CL, Ambinder R et al (1997) Phase II study of gemcitabine in patients with metastatic breast cancer. Eur J Cancer 33, S149 (abs 664)

10.

Spielman M, Kalla S, Llombart-Cussac A et al (1997) Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline-containing regimens. Eur J Cancer 33:S149 (abs 663)

11.

Rivera E (2003) Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 8(Suppl 2):3–9CrossRefPubMed

12.

Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC Jr, Hortobagyi GN (2001) Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19(6):1716–1722PubMed

13.

Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL 3rd, Pusztai L, Hortobagyi GN (2003) Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21(17):3249–3254CrossRefPubMed

14.

Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRef

15.

Hryniuk WM, Goodyear M (1990) The calculation of received dose intensity. J Clin Oncol 8(12):1935–1937PubMed

16.

Fabi A, Ferretti G, Salesi N, Papaldo P, Carlini P, Ciccarese M, Di Cocco B, Cecere F, Nardoni C, Felici A, Cognetti F (2005) Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients? Ann Oncol 16(3):516–517CrossRefPubMed

17.

Theodoulou M, Hudis C (2004) Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 100(10):2052–2063CrossRefPubMed

18.

Gabizon AA, Lyass O, Berry GJ, Wildgust M (2004) Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies.Cancer Invest 22(5):663–669CrossRefPubMed

19.

Wigler N, O’Brien M, Rosso R et al (2002) Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (CAELYX^TM/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 21:45a (abstr 177)

20.

Safra T, Muggia F, Jeffers S et al (2000) Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m². Ann Oncol 11:1029–1033CrossRefPubMed

21.

Berry G, Billingham M, Alderman E et al (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711–716CrossRefPubMed

22.

Mass R (2000) The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 27(6 Suppl 11):46–52PubMed

23.

Muss HB, Thor AD, Berry DA et al (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 5:330(18):1260–1266

24.

Zhang F, Yang Y, Smith T et al (2003) Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97(7):1758–1765CrossRefPubMed

25.

Moliterni A, Menard S, Valagussa P et al (2003) HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 21(3):458–462CrossRefPubMed

26.

Petit T, Borel C, Ghnassia JP et al (2001) Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 7(6):1577–1581PubMed

27.

Pegram MD, Finn RS, Arzoo K et al (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancers cells. Oncogene 15:537–547CrossRefPubMed

28.

Sledge GW (2001) Is HER-2/neu a predictor of anthracycline utility? No. J Natl Cancer Inst Monogr 30:85–87PubMed

29.

Paik S, Bryant J, Park C et al (1998) erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361–1370CrossRefPubMed

30.

Thor AD, Berry DA, Budman DR et al (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346–1360CrossRefPubMed

31.

Ravdin P, Green S, Albain K et al (1998) Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone [abstract]. Proc ASCO 17:97

32.

Dressler L, Berry D, Liu E et al (1999) Amplification of erbB2 by fluorescent in situ hybridization (FISH): an alternate method to predict outcome following dose-escalated CAF in stage II, node positive breast cancer patients. A Cancer and Leukemia Group B (CALGB) study [abstract]. Proc ASCO 18:75

33.

Ranson MR, Carmichael J, O’Byrne K et al (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 15:3185–3191PubMed

34.

Lyass O, Uziely B, Ben-Yosef R et al (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037–1047CrossRefPubMed

35.

Untch M, Eidtmann H, du Bois A et al (2004) Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 40(7):988–997CrossRefPubMed

36.

Buzdar AU, Ibrahim NK, Francis D et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676–3685CrossRefPubMed

37.

Chia SK, Clemenson M, Martin LA et al (2004) A multicenter phase II trial of pegylated liposomal doxorubicin and trastuzumab in Her-2 over-expressing metastatic breast cancer (MBC). Proc ASCO 23:630

38.

Park JW, Benz CC, Martin FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31(6 Suppl 13):196–205CrossRefPubMed

39.

Haider H, Kornek G, Kwasny W, Depisch D, Payrits T, Scheithauer W, Lang F (2004) Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC). Journal of Clinical Oncology ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement): 696

40.

Wong Z-W, Khoo K-S, Shah VA et al (2002) Phase I/II study of pegylated liposomal doxorubicin (PLD) and gemcitabine (G) as first-line therapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:49b (abstr 2008)

Title: Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients
Authors: Alessandra Fabi
Gianluigi Ferretti
Paola Papaldo
Nello Salesi
Mariangela Ciccarese
Vito Lorusso
Paolo Carlini
Armando Carpino
Marcella Mottolese
Anna Maria Cianciulli
Diana Giannarelli
Isabella Sperduti
Alessandra Felici
Francesco Cognetti
Publication date: 01-05-2006
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 5/2006
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-005-0116-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2006

Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models

High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer

CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines

Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice

Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer